This educational program consists of three presentations on several aspects of CV risk in diabetes.

This course consists of the following:

• The role for primary care in reducing CV risk in diabetes - Prof. Richard Hobbs, MD – Oxford, UK
• The role of GLP-1 receptor agonists in CVD prevention - Prof. Kamlesh Khunti, MD – Leicester, UK
• Newest ESC guidelines on diabetes and CVD - Prof. Francesco Cosentino, MD – Stockholm, Sweden

After watching these three videos, the learner should be able to:

• Discuss CV risk in patients with diabetes
• Explain how to reduce CV risk in patients with diabetes
• Identify effects of GLP-1RAs
• Recall findings from CVOTs with GLP-1RAs
• Describe recommendations for treatment of patients with diabetes in the 2019 ESC guidelines

Expert faculty

• Prof. Richard Hobbs, MD - Professor and Head, Nuffield Department of Primary Care Health Sciences, University of Oxford, United Kingdom.
• Prof. Kamlesh Kunti is professor of primary care diabetes and vascular medicine at the University of Leicester, UK.
• Prof. Francesco Cosentino is professor in Cardiovascular Medicine at the department of Cardiology at the Karolinska Institutet in Stockholm, Sweden.

Target audience

This educational activity is designed for cardiologists in secondary care and other healthcare professionals in primary care with an interest in diabetes.

CME accreditation

This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S